




LV MECHANICS AND TAVI. SOMETHING TO CONSIDER

Prof. J Zamorano
Head of Cardiology
Hospital Ramon y Cajal, Madrid



EuroValve
January 26-27, 2017




- **Reserch Grant.**

Boston and Edwards related to TAVI








- **What is related to durability ?**



**What should we
consider for long
term ?**







Long-Term Outcomes After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic Stenosis

The U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry

Mortality



Predictors of Mortality at 1 Year

870 patients

Variables	Multivariate Model	p Value
Edwards SAPIEN		
Medtronic CoreValve		
Route, other		
Route, transfemoral	0.73 (0.52–1.04)	0.08
AR moderate/severe	1.66 (1.10–2.51)	0.016
Major vascular complication		
Permanent pacemaker		
Male		
Age, yrs		
AV gradient		
LVEF ≥50%	1.00	
LVEF 30%–49%	1.49 (1.03–2.16)	0.03
LVEF <30%	1.65 (0.98–2.79)	0.06
NYHA functional class I/II		
NYHA functional class III/IV		
Coronary disease	1.23 (0.88–1.73)	0.23
Any previous cardiac surgery		
PVD		
Diabetes mellitus		
COPD	1.41 (1.00–1.98)	0.05
Creatinine >200 mmol/l	1.55 (0.90–2.68)	0.11

AR 1.66 (1.10–2.51)


Similar results at one year follow-up from the French registry Italian registry


Tamburino, C. *et al* *Circulation* 2011
Elchaninoff, H. *Eur. Heart J.* 2011

Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement

The NEW ENGLAND
JOURNAL of MEDICINE



Partner trial






CLINICAL IMPACT

Moderate o severe PAR. Hazard ratio for 1-year mortality





Paravalvular regurgitation: Is it relevant / frequent

AR Evolution at 1 years follow-up



Paravalvular leak in relation to post-procedure paravalvular leak



in the majority of the series, post-procedural aortic regurgitation **remains unchanged or tends to reduce**

Paravalvular regurgitation: Is it relevant / frequent

JL
N



The NEW ENGLAND
JOURNAL of MEDICINE

Partner trial



AR Evolution at 2 years follow-up

46.2%


Unchanged

31.5%

Improved

22.4%

Worse



The LVH response ! Diastole and/or Systole ?

JL
N




Acute left ventricle diastolic function improvement after transcatheter aortic valve implantation




Alexandra Gonçalves^{1,2}, Pedro Marcos-Alberca¹, Carlos Almeria¹, Gisela Feltes¹, Enrique Rodríguez¹, Rosa Ana Hernández-Antolín¹, Eulogio García¹, Luis Maroto¹, Cristina Fernandez Perez³, José C. Silva Cardoso², Carlos Macaya¹, and José Luis Zamorano^{1*}

- 61 patients with preserved LV systolic function submitted to successful TAVI.
- Parameters of diastolic function were evaluated before and minutes after TAVI.




This is the first study describing LV diastolic performance during TAVI. Immediate improvement in diastolic function parameters was described.

Paravalvular regurgitation: Changes in LV pressures



Paravalvular regurgitation: Chronic AR. Medical Tx

Chronic AR





What is new ?






Lv mechanics after TAVI

CENTRO	N	BL	DS	6M	12M
H. St Antonius NL	10				10
H. U. La Paz Madrid	21				21
H. U. Central Asturias	24				24
Cardiocentro Ticino	22				22
H. Reina Sofía	14				14
H. San Raffaele	2				2
H. U. Ramón y Cajal	10				10
H. Santiago Compostela	8				8
H. Guipuzkoa	5				5
H. La Timone France	1				0
	117				116




LV MASS, EF, AVA & Grad: **BL-DS**

	Corevalve		Lotus	
Ind. LV Mass Diff BL-DS	-15.17	0.0002	-11.10	0.0102
Diff LVEF Simpson BL- DS	+2.13%	0.0259	-0.31%	0.7704
Diff AVA BL- DS	+1.36	0.0000	+1.02	0.0000
Diff Gradient BL-DS	-40.96	0.0000	-28.81	0.0000



LV MASS, EF, AVA & Peak G: **BL-12M**

	Corevalve		Lotus	
Diff LV mass index BL-12Mo	-30.79	0.0000	-25.25	0.0051
Diff LV EF Simpson BL-12Mo	+4.92%	0.0026	+3.74%	0.0807
Diff AVA BL-12Mo	+1.35	0.0000	+0.74	0.0000
Diff Grad BL-12Mo	-42.53	0.0000	-26.42	0.0000



TAVI & GLS **6Mo**- According to AVA


		Δ Coreval ve			Δ Lotus	
AVA > 1.5	31	-2.86	0.0025	26	-1.47	0.0498



TAVI & GLS 12Mo- According to AVA



		Δ Coreval ve			Δ Lotus	
GP medio <30	50	-3.60	0.0000	29	-1.88	0.0344
GP medio <40	50	-3.60	0.0000	29	-1.88	0.0344



What may influence in long term results after TAVI

- Still needed LONG Term FU
- Focus in Ao Reg..... Mortality
- Focus in Diastolic function. Short term filling pressures. Acute changes
- Focus Systolic function. LV mechanics also changes and needs to be correlated with Long term prognosis